We are a global pharmaceutical Group governed by a non-profit Foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to transmit to future generations a world that can ensure access to quality health care for all.
Relying on a solid geographical presence and revenue of €4.7 billion in 2020 achieved in 150 countries, we employ 22,500 people worldwide. We are an independent group that invests over 20% of its brand-name revenue in Research and Development every year.
A leader in cardiology, our ambition is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative diseases. To promote access to healthcare for all, we also offer a range of quality generic medicines covering most pathologies.
Our four research centers are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centers around the world. 98% of Servier brand-name medicines active ingredients are synthesized in its own plant in Bolbec-Baclair in France.
To accelerate therapeutic innovation for the benefit of patients, we are committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. We also integrate the patient’s voice at the heart of our activities, from research to support beyond the pill.
All Group employees are driven by shared Values and guided by a common Vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.
With 100 million of patients treated each day worldwide by our medicines, we are keenly aware of our responsibilities to patients, doctors and health care professionals. They are the motivating force behind our daily drive for innovation as a provider of therapeutic progress.